Pyoderma gangrenosum treated with secukinumab: A case report

McPhie, Meghan L.; Kirchhof, Mark G.

doi:10.1177/2050313x20940430

Cited by 19 publications

(22 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-tumor necrosis alpha inhibitors were also found to facilitate a faster wound healing of PG lesions than steroids alone [27]. Additional therapeutic options used in the successful treatment of PG target other cytokines in the inflammatory cascade, including IL-12/IL-23 (ustekinumab) [28], IL-17 (secukinumab) [29], IL-1β (canakinumab) [30], IL-1 Receptor I (anakinra) [31], IL-6 (tocilizumab) [19], JAK1,2 and 3 (tofacitinib and ruxolitinib) [32,33], and phosphodiesterase 4 (PDE4) (apremilast) [34]. There is also evidence that intravenous immune globulin (IVIG) can be used successfully as an adjuvant treatment for PG [35][36][37].…”

Section: Treatmentmentioning

confidence: 99%

Pyoderma Gangrenosum: A Review of Updates in Diagnosis, Pathophysiology and Management

Skopis

Bag-Ozbek

2021

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a rare entity that is characterized by infiltration of neutrophils into the dermis, causing the formation of rapidly enlarging, painful and necrotic skin ulcers. The pathophysiology of PG is still poorly understood. However, genetic, autoimmune and autoinflammatory mechanisms have been proposed that could potentially explain the etiology of this ulcerating skin disorder. Early diagnosis and treatment are key, as the disease course is rapidly progressive and can leave disfiguring, cribriform scars. However, the diagnosis of PG proves difficult, firstly because there are multiple variants of the disease and secondly because it is a clinical diagnosis and can appear similar to that of other diseases such as vasculitis, skin/soft tissue infections and malignancy. Additionally, there are no official diagnostic criteria to aid in the recognition of PG, which often leads to significant delays in diagnosis. The treatment of PG consists in immunosuppression. However, due to a lack of standardized guidelines, therapeutic regimens are usually dependent upon the individual clinician’s experience and are based on little evidence. Knowledge of the clinical features and pathophysiology of PG can aid in early diagnosis and targeted treatment strategies, which in turn results in improved patient outcomes.

show abstract

Section: Treatmentmentioning

confidence: 99%

Pyoderma Gangrenosum: A Review of Updates in Diagnosis, Pathophysiology and Management

Skopis

Bag-Ozbek

2021

View full text Add to dashboard Cite

show abstract

“…It has been reported that PG responds well to biologics against IL-1β, 13 IL-12, 14 IL-17, 15 IL-23, 16 IL-1 receptor, 17 IL-6 receptor 18 and most commonly TNF. 19 The T helper (Th)17/TNF-α axis leading to neutrophil infiltration has been shown in the pathogenetic basis of psoriasis, 20 PPP 8 and PG.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of a Patient with Pyoderma Gangrenosum, Plaque Psoriasis and Palmoplantar Pustulosis with Adalimumab

Chu¹,

Liu²,

Bai³

et al. 2022

CCID

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a rare autoinflammatory skin disorder, which is characterised by rapidly developing and tender cutaneous ulcers. The treatment of PG is challenging. Palmoplantar pustulosis (PPP) is also an autoinflammatory dermatosis with sterile pustules on the palms and/or the soles. We demonstrated a 68-year-old patient with coexisting autoinflammatory diseases including PG, 1-year history of plaque psoriasis and PPP, recovered after treatment with adalimumab. We also reviewed published reports of PG-associated autoinflammatory syndromes with adalimumab.

show abstract

“…However, uncontrolled IL-17A activity has a negative impact on the wound-healing process by intensifying the inflammatory response via pro-inflammatory cytokines’ production as evident in chronic wounds. Most importantly, case reports of the use of Ustekinumab (anti-IL23 monoclonal antibody) and Secukinumab or Ixekizumab (anti-IL17A monoclonal antibody) treatments in pyoderma gangrenosum (a skin ulceration condition as a comorbidity of other chronic inflammatory diseases) show improved wound healing without compromising keratinocyte function [ 128 , 129 , 130 , 131 ].…”

Section: Strategies To Modulate Wound Inflammation and Macrophage Act...mentioning

confidence: 99%

Macrophages in Skin Wounds: Functions and Therapeutic Potential

et al. 2022

View full text Add to dashboard Cite

Macrophages regulate cutaneous wound healing by immune surveillance, tissue repair and remodelling. The depletion of dermal macrophages during the early and middle stages of wound healing has a detrimental impact on wound closure, characterised by reduced vessel density, fibroblast and myofibroblast proliferation, delayed re-epithelization and abated post-healing fibrosis and scar formation. However, in some animal species, oral mucosa and foetal life, cutaneous wounds can heal normally and remain scarless without any involvement of macrophages. These paradoxical observations have created much controversy on macrophages’ indispensable role in skin wound healing. Advanced knowledge gained by characterising macrophage subsets, their plasticity in switching phenotypes and molecular drivers provides new insights into their functional importance during cutaneous wound healing. In this review, we highlight the recent findings on skin macrophage subsets, their functional role in adult cutaneous wound healing and the potential benefits of targeting them for therapeutic use.

show abstract

Pyoderma gangrenosum treated with secukinumab: A case report

Cited by 19 publications

References 16 publications

Pyoderma Gangrenosum: A Review of Updates in Diagnosis, Pathophysiology and Management

Pyoderma Gangrenosum: A Review of Updates in Diagnosis, Pathophysiology and Management

Successful Treatment of a Patient with Pyoderma Gangrenosum, Plaque Psoriasis and Palmoplantar Pustulosis with Adalimumab

Macrophages in Skin Wounds: Functions and Therapeutic Potential

Contact Info

Product

Resources

About